Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

n, of which $8.5 million was related to cost sharing and $18.1 million was related to the Excess Amounts, which are due to be received during our quarter ending March 31, 2013. At June 30, 2012, the Company had $5.8 million due from Janssen related to cost sharing. At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million.

The Company expects to end calendar year 2013 with cash, cash equivalents and marketable securities of more than $225 million.

"Ibrutinib has demonstrated great clinical progress during this past year. Today we have a very solid development program in place with 5 Phase III trials initiated and several more trials to be started this year. We were honored to announce this past Tuesday that ibrutinib received Breakthrough Designation in two B-cell malignancies. We look forward to working with the FDA to bring this therapy to market in a timely manner," said Bob Duggan, CEO and Chairman of the Board. "Looking ahead, our goals for this year are star high as we are continuing to unfold our clinical program. With our partner Janssen, we are committed to a shared vision of patient friendly, body harmonious solutions intended to improve the quality of life, increase duration of life and resolve serious medical health care needs for patients."

Recent Developments & HighlightsBreakthrough Therapy Designation

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacyclics, together
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue: India Solid Waste Management ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... main governing bodies responsible for complete handling and ... an average, around 135,000 MT solid waste is ...
(Date:9/1/2014)... September 01, 2014 The Collaborative ... Diagnostics report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science companies. ... analysis of how and why companies enter collaborative ... prospective partner’s negotiated deals terms provides critical insight ...
(Date:8/31/2014)... 2014 Available spectra is similar ... research and cultivation of a wide range of ... LEDs with proven patented and pending wide spectrum ... uniformity in critical applications in contrast to growth ... “Our customers have a large variety of differently ...
(Date:8/31/2014)... This is a professional and in-depth ... Hardener industry in Global and China. The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
Breaking Biology Technology:India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... Identify Potential Initiation Dosing Regimen , ... palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant ... of a 13-week study presented today (1). Statistical ... and 150 mg equivalent [eq.a]), when given every 4 ...
... the Journal Blood for the American Society of Hematology Annual ... Dec. 10 Alfacell Corporation (Nasdaq: ACEL ) ... abstracts in Blood (2008 112: Abstract 4205 & ... (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia (CLL) and ...
... Calif., Dec. 10 Valeant,Pharmaceuticals International (NYSE: ... signed a,definitive agreement to acquire Dow Pharmaceutical Sciences, ... the development of topical,products on a proprietary basis, ... The transaction significantly enhances Valeant,s,dermatology franchise in the ...
Cached Biology Technology:Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 2Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 3Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 5Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 6Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 7Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 8Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 9Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 2Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 3Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 4Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 5
(Date:9/2/2014)... Passerine birds, also known as perching birds, that migrate ... they do in autumn to reach their destinations. This ... birds that only make short migratory flights, says researcher ... journal Behavioral Ecology and Sociobiology . , ... used a tracking radar to measure over three years ...
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
Breaking Biology News(10 mins):Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... speech President Bush said technology is the best way to ... Energy Joint Genome Institute (DOE JGI) is directing the technology ... will lead to cheaper and easier to produce biofuels. ... molecular biology we can generate diagnostic fingerprints, Environmental Genomic Tags ...
... the March 24 Cell reports the discovery of a ... could offer a potential new target for countermeasures against ... therapies might have the potential to protect against anthrax ... have lost their therapeutic value, they added. , The ...
... Scientists have for many years debated the cause of ... Papagrigorakis and colleagues using DNA collected from teeth from ... as the disease responsible for this devastating epidemic. The ... Journal of Infectious Diseases (IJID) published by Elsevier on ...
Cached Biology News:Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy 2Driver of anthrax toxicity could lead to late-stage therapy 2Typhoid fever led to the fall of Athens 2
... Reagents are complete ready-to-use reagents for the ... is specifically formulated for the isolation of ... is specifically formulated for the isolation of ... with DNAzol Reagents can be used for ...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: